share_log

Virpax Pharmaceuticals | ARS: Annual Report to Security Holders

SEC ·  Jun 13 05:13
Summary by Futu AI
Virpax Pharmaceuticals has made an announcement regarding the launch of Epoladerm™, a new non-opioid pain management product. Epoladerm™ is presented as a diclofenac epolamine spray film, specifically formulated to treat acute pain associated with minor injuries such as strains, sprains, and contusions. The company has underscored the significance of Epoladerm™, particularly its non-opioid characteristic and user-friendly spray film application, which aligns with Virpax's dedication to providing alternative pain management options in the midst of the ongoing opioid crisis.
Virpax Pharmaceuticals has made an announcement regarding the launch of Epoladerm™, a new non-opioid pain management product. Epoladerm™ is presented as a diclofenac epolamine spray film, specifically formulated to treat acute pain associated with minor injuries such as strains, sprains, and contusions. The company has underscored the significance of Epoladerm™, particularly its non-opioid characteristic and user-friendly spray film application, which aligns with Virpax's dedication to providing alternative pain management options in the midst of the ongoing opioid crisis.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.